Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comprehensive criteria for assessing therapy-induced toxicity.

J A Ajani1, S R Welch, M N Raber

  • 1Division of Medicine, University of Texas, M.D. Anderson Cancer Center, Houston 77030.

Cancer Investigation
|January 1, 1990
PubMed
Summary

Standardized criteria are needed for reporting therapy-induced toxic reactions. This study introduces objective methods to improve the accuracy and consistency of toxicity grading in clinical research and drug development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel study.

ESMO gastrointestinal oncology·2026
Same author

Disease-free survival as surrogate for overall survival in real-world settings for esophageal cancer: an analysis of SEER-Medicare data.

ESMO open·2024
Same author

Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials.

ESMO open·2024
Same author

Vaccination with the Crimean-Congo hemorrhagic fever virus viral replicon vaccine induces NP-based T-cell activation and antibodies possessing Fc-mediated effector functions.

Frontiers in cellular and infection microbiology·2023
Same author

Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma.

The British journal of surgery·2021

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Biostatistics

Background:

  • Current methods for assessing and reporting therapy-induced toxic reactions, especially from chemotherapy, lack standardization.
  • The inconsistent quality of toxicity reporting hinders reliable clinical research, drug development, and complex treatment implementation.
  • Unlike therapeutic response, objective criteria for toxicity assessment are not widely established.

Purpose of the Study:

  • To develop comprehensive and objective criteria for assessing and reporting toxic reactions.
  • To reduce subjectivity in toxicity grading through the use of primarily objective methods.
  • To standardize the "morbidity impact" of toxicity grades across different organ systems.

Main Methods:

  • Development of novel, comprehensive criteria for toxicity assessment.

Related Experiment Videos

  • Implementation of primarily objective measures to minimize grading subjectivity.
  • Standardization of toxicity grading to reflect morbidity impact regardless of organ system.

    • Main Results:

    • Established comprehensive criteria for reliable toxicity assessment and reporting.
    • Significantly reduced subjectivity in toxicity grading by employing objective methods.
    • Standardized the impact of toxicity grades across various organ systems.

    Conclusions:

    • The developed criteria provide a standardized, objective framework for reporting therapy-induced toxic reactions.
    • Improved toxicity reporting will enhance the quality of clinical research, drug development, and patient treatment.
    • This standardized approach addresses a critical unmet need in clinical oncology and pharmacology.